FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382011019> ?p ?o ?g. }

• W4382011019 endingPage "675" @default.
• W4382011019 startingPage "669" @default.
• W4382011019 abstract "Interleukin (IL) 23p19 monoclonal antibodies were efficacious and safe in the treatment of psoriasis. A first-in-human (FIH) study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of IBI112, a novel IL-23p19 monoclonal antibody.In this FIH, randomized, double-blind, placebo-controlled, single-ascending-dose study, a subcutaneous (SC, 5-600 mg) or intravenous (IV, 100 and 600 mg) or placebo was administered to eligible healthy subjects. Safety was assessed by physical examinations, vital signs, laboratory tests, and electrocardiograms. Furthermore, non-compartment analysis and population PK modeling were conducted to characterize PK, and model-based simulation was applied to justify dose selection for psoriasis patients.A total of 46 subjects were enrolled, with 35 receiving IBI112 and 11 receiving placebo. No serious adverse events (SAEs) and no clinically significant adverse events were identified. After a single SC of IBI112, the median Tmax was 4-10.5 days, and the half-life (t1/2) ranged from 21.8 to 35.8 days. IBI112 exposures (Cmax and AUCinf) approached dose proportionality across 5-300 mg range.IBI112 was well tolerated and safe at SC or IV dose up to 600 mg and showed a linear PK characteristics at SC dose from 5 to 300 mg.ClinicalTrial.gov NCT04511624." @default.
• W4382011019 created "2023-06-27" @default.
• W4382011019 creator A5014393752 @default.
• W4382011019 creator A5014800323 @default.
• W4382011019 creator A5017947172 @default.
• W4382011019 creator A5019598632 @default.
• W4382011019 creator A5051375985 @default.
• W4382011019 creator A5052596016 @default.
• W4382011019 creator A5059780278 @default.
• W4382011019 creator A5062293671 @default.
• W4382011019 creator A5062812012 @default.
• W4382011019 creator A5067221645 @default.
• W4382011019 creator A5070864870 @default.
• W4382011019 creator A5070904383 @default.
• W4382011019 creator A5082115156 @default.
• W4382011019 date "2023-06-29" @default.
• W4382011019 modified "2023-10-16" @default.
• W4382011019 title "Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study" @default.
• W4382011019 cites W1555185942 @default.
• W4382011019 cites W1787578841 @default.
• W4382011019 cites W1967275179 @default.
• W4382011019 cites W1973771269 @default.
• W4382011019 cites W2012322080 @default.
• W4382011019 cites W2040624495 @default.
• W4382011019 cites W2087905758 @default.
• W4382011019 cites W2126048371 @default.
• W4382011019 cites W2142051176 @default.
• W4382011019 cites W2181278642 @default.
• W4382011019 cites W2510661649 @default.
• W4382011019 cites W2743993411 @default.
• W4382011019 cites W2783424399 @default.
• W4382011019 cites W2801085776 @default.
• W4382011019 cites W2897426023 @default.
• W4382011019 cites W2954736489 @default.
• W4382011019 cites W3029724060 @default.
• W4382011019 cites W3092765421 @default.
• W4382011019 cites W3100055007 @default.
• W4382011019 cites W4241643874 @default.
• W4382011019 doi "https://doi.org/10.1080/13543784.2023.2230122" @default.
• W4382011019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37358916" @default.
• W4382011019 hasPublicationYear "2023" @default.
• W4382011019 type Work @default.
• W4382011019 citedByCount "0" @default.
• W4382011019 crossrefType "journal-article" @default.
• W4382011019 hasAuthorship W4382011019A5014393752 @default.
• W4382011019 hasAuthorship W4382011019A5014800323 @default.
• W4382011019 hasAuthorship W4382011019A5017947172 @default.
• W4382011019 hasAuthorship W4382011019A5019598632 @default.
• W4382011019 hasAuthorship W4382011019A5051375985 @default.
• W4382011019 hasAuthorship W4382011019A5052596016 @default.
• W4382011019 hasAuthorship W4382011019A5059780278 @default.
• W4382011019 hasAuthorship W4382011019A5062293671 @default.
• W4382011019 hasAuthorship W4382011019A5062812012 @default.
• W4382011019 hasAuthorship W4382011019A5067221645 @default.
• W4382011019 hasAuthorship W4382011019A5070864870 @default.
• W4382011019 hasAuthorship W4382011019A5070904383 @default.
• W4382011019 hasAuthorship W4382011019A5082115156 @default.
• W4382011019 hasConcept C112705442 @default.
• W4382011019 hasConcept C126322002 @default.
• W4382011019 hasConcept C142724271 @default.
• W4382011019 hasConcept C197934379 @default.
• W4382011019 hasConcept C203014093 @default.
• W4382011019 hasConcept C204787440 @default.
• W4382011019 hasConcept C22979827 @default.
• W4382011019 hasConcept C27081682 @default.
• W4382011019 hasConcept C2777288759 @default.
• W4382011019 hasConcept C2778375690 @default.
• W4382011019 hasConcept C2780564577 @default.
• W4382011019 hasConcept C2908647359 @default.
• W4382011019 hasConcept C71924100 @default.
• W4382011019 hasConcept C90924648 @default.
• W4382011019 hasConcept C98274493 @default.
• W4382011019 hasConcept C99454951 @default.
• W4382011019 hasConceptScore W4382011019C112705442 @default.
• W4382011019 hasConceptScore W4382011019C126322002 @default.
• W4382011019 hasConceptScore W4382011019C142724271 @default.
• W4382011019 hasConceptScore W4382011019C197934379 @default.
• W4382011019 hasConceptScore W4382011019C203014093 @default.
• W4382011019 hasConceptScore W4382011019C204787440 @default.
• W4382011019 hasConceptScore W4382011019C22979827 @default.
• W4382011019 hasConceptScore W4382011019C27081682 @default.
• W4382011019 hasConceptScore W4382011019C2777288759 @default.
• W4382011019 hasConceptScore W4382011019C2778375690 @default.
• W4382011019 hasConceptScore W4382011019C2780564577 @default.
• W4382011019 hasConceptScore W4382011019C2908647359 @default.
• W4382011019 hasConceptScore W4382011019C71924100 @default.
• W4382011019 hasConceptScore W4382011019C90924648 @default.
• W4382011019 hasConceptScore W4382011019C98274493 @default.
• W4382011019 hasConceptScore W4382011019C99454951 @default.
• W4382011019 hasIssue "7" @default.
• W4382011019 hasLocation W43820110191 @default.
• W4382011019 hasLocation W43820110192 @default.
• W4382011019 hasOpenAccess W4382011019 @default.
• W4382011019 hasPrimaryLocation W43820110191 @default.
• W4382011019 hasRelatedWork W1994361489 @default.
• W4382011019 hasRelatedWork W2037651778 @default.
• W4382011019 hasRelatedWork W2051764329 @default.
• W4382011019 hasRelatedWork W2064759457 @default.

• next